162 results
8-K
EX-99.1
ALKS
Alkermes plc
1 May 24
Alkermes plc Reports First Quarter 2024 Financial Results
7:05am
director Nancy S. Lurker to the company’s board of directors.
In April 2024, the company presented data from its long-term safety study of LYBALVI
8-K
EX-99.1
ALKS
Alkermes plc
9 Apr 24
Regulation FD Disclosure
7:09am
populations at all doses tested.
The phase 1b NT2 (n=9) and IH (n=8) study cohorts evaluated the safety, tolerability, pharmacokinetics and pharmacodynamics … from 3 mg to 25 mg strengths for up to 10 days. The objectives of this part of the study were to assess ALKS 2680’s safety, tolerability
8-K
EX-99.1
6tvn8pp diw2tl
15 Feb 24
Results of Operations and Financial Condition
7:05am
8-K
EX-99.1
yjz3 oiv5sqs733
8 Jan 24
Regulation FD Disclosure
7:00am
8-K
EX-10.3
3khza1mf5
15 Nov 23
Alkermes Completes Separation of Oncology Business
7:05am
8-K
EX-10.4
rqpkr
15 Nov 23
Alkermes Completes Separation of Oncology Business
7:05am
8-K
EX-99.2
wsp39sm5e1qm7v
15 Nov 23
Alkermes Completes Separation of Oncology Business
7:05am
8-K
EX-99.1
nyqpey m1n
25 Oct 23
Alkermes plc Reports Third Quarter 2023 Financial Results
7:06am
8-K
EX-99.2
oizc935ujf1sspjiy
25 Oct 23
Alkermes plc Reports Third Quarter 2023 Financial Results
7:06am